Innoviva (INVA) | Financial Analysis & Statements
Innoviva Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
114.6M
Gross Profit
101.9M
88.95%
Operating Income
39.0M
34.02%
Net Income
164.2M
143.22%
Balance Sheet Metrics
Total Assets
1.6B
Total Liabilities
462.3M
Shareholders Equity
1.2B
Debt to Equity
0.39
Cash Flow Metrics
Operating Cash Flow
204.1M
Free Cash Flow
54.5M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Innoviva Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 411.3M | 358.7M | 310.5M | 331.3M | 391.9M |
| Cost of Goods Sold | 77.4M | 36.6M | 42.6M | 13.8M | 0 |
| Gross Profit | 333.9M | 322.1M | 267.8M | 317.5M | 391.9M |
| Gross Margin % | 81.2% | 89.8% | 86.3% | 95.8% | 100.0% |
| Operating Expenses | |||||
| Research & Development | 30.6M | 13.7M | 33.9M | 41.4M | 576.0K |
| Selling, General & Administrative | 113.3M | 115.7M | 98.2M | 63.5M | 16.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 143.9M | 129.3M | 132.2M | 105.0M | 16.8M |
| Operating Income | 163.7M | 166.9M | 113.9M | 207.0M | 375.1M |
| Operating Margin % | 39.8% | 46.5% | 36.7% | 62.5% | 95.7% |
| Non-Operating Items | |||||
| Interest Income | 21.1M | 19.1M | 15.8M | 6.4M | 1.8M |
| Interest Expense | 16.7M | 22.2M | 19.2M | 15.8M | 19.1M |
| Other Non-Operating Income | 158.7M | -126.4M | 83.6M | 89.4M | 87.4M |
| Pre-tax Income | 326.9M | 37.4M | 194.1M | 286.9M | 445.3M |
| Income Tax | 55.7M | 14.0M | 14.4M | 66.7M | 76.4M |
| Effective Tax Rate % | 17.0% | 37.4% | 7.4% | 23.2% | 17.2% |
| Net Income | 271.2M | 23.4M | 179.7M | 220.3M | 368.8M |
| Net Margin % | 65.9% | 6.5% | 57.9% | 66.5% | 94.1% |
| Key Metrics | |||||
| EBITDA | 349.7M | 144.7M | 223.9M | 53.8M | 457.7M |
| EPS (Basic) | $4.02 | $0.37 | $2.75 | $3.07 | $3.24 |
| EPS (Diluted) | $3.30 | $0.36 | $2.20 | $2.37 | $2.87 |
| Basic Shares Outstanding | 67395000 | 62726000 | 65435000 | 69644000 | 82062000 |
| Diluted Shares Outstanding | 67395000 | 62726000 | 65435000 | 69644000 | 82062000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Innoviva Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 550.9M | 305.0M | 193.5M | 291.0M | 201.5M |
| Short-term Investments | 15.7M | 107.5M | - | - | - |
| Accounts Receivable | 35.0M | 20.4M | 14.5M | 9.4M | 110.7M |
| Inventory | 39.2M | 33.7M | 40.7M | 55.9M | 0 |
| Other Current Assets | 1.6M | 656.0K | 4.3M | 2.9M | 1.4M |
| Total Current Assets | 727.5M | 554.3M | 344.2M | 443.5M | 313.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 12.5M | 3.0M | 3.0M | 3.4M | 109.0K |
| Goodwill | 218.0M | 244.2M | 266.1M | 306.3M | 0 |
| Intangible Assets | 182.2M | 208.4M | 230.3M | 252.9M | 10.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 153.0M | 193.5M | 170.8M | 199.5M | 240.2M |
| Total Non-Current Assets | 907.6M | 746.8M | 899.3M | 788.0M | 612.7M |
| Total Assets | 1.6B | 1.3B | 1.2B | 1.2B | 926.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 5.0M | 2.1M | 6.7M | 2.9M | 27.0K |
| Short-term Debt | 418.0K | 193.6M | 1.2M | 97.5M | 106.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | -4.3M | - | - | 2.6M | - |
| Total Current Liabilities | 49.7M | 236.1M | 38.1M | 135.0M | 5.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 268.6M | 257.5M | 447.9M | 446.6M | 394.7M |
| Deferred Tax Liabilities | 31.8M | 0 | 563.0K | 5.8M | 0 |
| Other Non-Current Liabilities | 1.1M | - | 359.0K | 595.0K | - |
| Total Non-Current Liabilities | 412.6M | 373.8M | 530.4M | 530.7M | 394.7M |
| Total Liabilities | 462.3M | 609.9M | 568.6M | 665.7M | 400.5M |
| Equity | |||||
| Common Stock | 747.0K | 627.0K | 633.0K | 692.0K | 696.0K |
| Retained Earnings | 269.4M | -1.8M | -25.2M | -204.9M | -456.1M |
| Treasury Stock | - | 0 | 393.8M | 393.8M | 393.8M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.2B | 691.2M | 675.0M | 565.8M | 525.9M |
| Key Metrics | |||||
| Total Debt | 269.0M | 451.1M | 449.1M | 544.1M | 394.8M |
| Working Capital | 677.8M | 318.2M | 306.1M | 308.5M | 307.9M |
Balance Sheet Composition
Innoviva Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 271.2M | 23.4M | 179.7M | 220.3M | 368.8M |
| Depreciation & Amortization | 26.3M | 25.9M | 21.8M | 5.6M | 0 |
| Stock-Based Compensation | 9.5M | 6.4M | 5.8M | 7.3M | 2.0M |
| Working Capital Changes | -15.0M | -52.0M | -32.0M | 6.1M | -15.8M |
| Operating Cash Flow | 358.3M | 20.2M | 222.4M | 293.7M | 454.1M |
| Investing Activities | |||||
| Capital Expenditures | -1.1M | -169.0K | -411.0K | -67.0K | 0 |
| Acquisitions | 28.2M | 43.5M | 41.3M | 30.5M | -213.5M |
| Investment Purchases | -78.4M | -103.1M | -107.7M | -87.1M | -22.3M |
| Investment Sales | 101.2M | - | - | 0 | 279.5M |
| Investing Cash Flow | 49.9M | -59.8M | -66.8M | -56.6M | 43.7M |
| Financing Activities | |||||
| Share Repurchases | -4.7M | -14.9M | -75.8M | -8.6M | -394.2M |
| Dividends Paid | - | - | - | - | 0 |
| Debt Issuance | - | 0 | 0 | 252.5M | 0 |
| Debt Repayment | 0 | 0 | -96.2M | -165.1M | 0 |
| Financing Cash Flow | -2.1M | -13.5M | -268.0M | -220.7M | -452.5M |
| Free Cash Flow | 186.4M | 184.4M | 140.7M | 201.7M | 363.8M |
| Net Change in Cash | 406.1M | -53.0M | -112.4M | 16.3M | 45.4M |
Cash Flow Trend
Innoviva Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
7.15
Forward P/E
10.68
Price to Book
1.50
Price to Sales
4.28
PEG Ratio
0.01
Profitability Ratios
Profit Margin
65.92%
Operating Margin
34.66%
Return on Equity
29.10%
Return on Assets
7.18%
Financial Health
Current Ratio
14.64
Debt to Equity
28.24
Beta
0.40
Per Share Data
EPS (TTM)
$3.30
Book Value per Share
$15.71
Revenue per Share
$6.10
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| INVA | 1.8B | 7.15 | 1.50 | 29.10% | 65.92% | 28.24 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






